Overview

The marketing authorisation for Imatinib Medac has been withdrawn at the request of the marketing authorisation holder.

Imatinib medac : EPAR - Summary for the public

български (BG) (732.95 KB - PDF)
español (ES) (645.85 KB - PDF)
čeština (CS) (709.92 KB - PDF)
dansk (DA) (646.49 KB - PDF)
Deutsch (DE) (646.71 KB - PDF)
eesti keel (ET) (647.15 KB - PDF)
ελληνικά (EL) (731.71 KB - PDF)
français (FR) (641.98 KB - PDF)
hrvatski (HR) (657.5 KB - PDF)
italiano (IT) (640.34 KB - PDF)
latviešu valoda (LV) (728.96 KB - PDF)
lietuvių kalba (LT) (690.93 KB - PDF)
magyar (HU) (704.2 KB - PDF)
Malti (MT) (710.17 KB - PDF)
Nederlands (NL) (646.06 KB - PDF)
polski (PL) (710.5 KB - PDF)
português (PT) (642.51 KB - PDF)
română (RO) (660.01 KB - PDF)
slovenčina (SK) (709.86 KB - PDF)
slovenščina (SL) (702.54 KB - PDF)
Suomi (FI) (646.31 KB - PDF)
svenska (SV) (641.5 KB - PDF)

Product information

Imatinib medac : EPAR - Product Information

български (BG) (2.26 MB - PDF)
español (ES) (941.25 KB - PDF)
čeština (CS) (1.85 MB - PDF)
dansk (DA) (1016.75 KB - PDF)
Deutsch (DE) (1.32 MB - PDF)
eesti keel (ET) (960.1 KB - PDF)
ελληνικά (EL) (2.26 MB - PDF)
français (FR) (1.06 MB - PDF)
hrvatski (HR) (1.02 MB - PDF)
íslenska (IS) (1.01 MB - PDF)
italiano (IT) (1017.88 KB - PDF)
latviešu valoda (LV) (1.81 MB - PDF)
lietuvių kalba (LT) (1.05 MB - PDF)
magyar (HU) (1.73 MB - PDF)
Malti (MT) (1.8 MB - PDF)
Nederlands (NL) (1022.38 KB - PDF)
norsk (NO) (1009.64 KB - PDF)
polski (PL) (1.8 MB - PDF)
português (PT) (994.47 KB - PDF)
română (RO) (1.12 MB - PDF)
slovenčina (SK) (1.74 MB - PDF)
slovenščina (SL) (1.71 MB - PDF)
Suomi (FI) (1.27 MB - PDF)
svenska (SV) (1008.63 KB - PDF)

Latest procedure affecting product information: IB/0009

11/04/2018

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Imatinib medac : EPAR - All Authorised presentations

български (BG) (616.45 KB - PDF)
español (ES) (575.28 KB - PDF)
čeština (CS) (598.04 KB - PDF)
dansk (DA) (574.72 KB - PDF)
Deutsch (DE) (574.39 KB - PDF)
eesti keel (ET) (575.57 KB - PDF)
ελληνικά (EL) (616.71 KB - PDF)
français (FR) (575.47 KB - PDF)
hrvatski (HR) (584.78 KB - PDF)
íslenska (IS) (575.29 KB - PDF)
italiano (IT) (19.47 KB - PDF)
latviešu valoda (LV) (609.21 KB - PDF)
lietuvių kalba (LT) (605.7 KB - PDF)
magyar (HU) (597.42 KB - PDF)
Malti (MT) (603.63 KB - PDF)
Nederlands (NL) (574.55 KB - PDF)
norsk (NO) (574.35 KB - PDF)
polski (PL) (605.1 KB - PDF)
português (PT) (574.34 KB - PDF)
română (RO) (588.88 KB - PDF)
slovenčina (SK) (604.94 KB - PDF)
slovenščina (SL) (26.43 KB - PDF)
Suomi (FI) (576.16 KB - PDF)
svenska (SV) (574.95 KB - PDF)

Product details

Name of medicine
Imatinib medac
Active substance
imatinib
International non-proprietary name (INN) or common name
imatinib
Therapeutic area (MeSH)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Dermatofibrosarcoma
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Myelodysplastic-Myeloproliferative Diseases
  • Hypereosinophilic Syndrome
Anatomical therapeutic chemical (ATC) code
L01XE01

Pharmacotherapeutic group

Protein kinase inhibitors

Therapeutic indication

Imatinib medac is indicated for the treatment of:

  • paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;
  • paediatric patients with Ph+CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase;
  • adult and paediatric patients with Ph+CML in blast crisis;
  • adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) integrated with chemotherapy;
  • adult patients with relapsed or refractory Ph+ALL as monotherapy;
  • adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;
  • adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement;
  • adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

The effect of imatinib on the outcome of bone marrow transplantation has not been determined.

In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP.

The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

Authorisation details

EMA product number
EMEA/H/C/002692

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Medac

Gesellschaft fuer Spezialpraeparaten mbH
Theater strasse 6
22880 Wedel
Germany

Marketing authorisation issued
25/09/2013
Revision
5

Assessment history

Imatinib medac : EPAR - Procedural steps taken and scientific information after authorisation

Imatinib medac : EPAR - Public assessment report

CHMP summary of positive opinion for Imatinib medac

This page was last updated on

How useful do you find this page?